Literature DB >> 8556220

Reference tables for the intrasubject coefficient of variation in bioequivalence studies.

V W Steinijans1, R Sauter, D Hauschke, E Diletti, R Schall, H G Luus, M Elze, H Blume, C Hoffmann, G Franke.   

Abstract

Bioequivalence studies are usually performed as crossover studies and, therefore, information on the intrasubject coefficient of variation is needed for sample size planning. However, this information is usually not accessible in publications on bioequivalence studies, and only the pooled inter- and intrasubject coefficient of variation for either test or reference formulation is reported. It is the purpose of the present communication to provide reference values of the intrasubject coefficient of variation for various previously investigated drugs. The presentation includes pertinent pharmacokinetic characteristics for immediate- and extended-release formulations in single- and multiple-dose crossover studies.

Mesh:

Substances:

Year:  1995        PMID: 8556220

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Ther        ISSN: 0946-1965            Impact factor:   1.366


  11 in total

1.  The role of metabolites in bioequivalency assessment. III. Highly variable drugs with linear kinetics and first-pass effect.

Authors:  A J Jackson
Journal:  Pharm Res       Date:  2000-11       Impact factor: 4.200

2.  Including information on the therapeutic window in bioequivalence acceptance.

Authors:  Tom Jacobs; Filip De Ridder; Sarah Rusch; Achiel Van Peer; Geert Molenberghs; Luc Bijnens
Journal:  Pharm Res       Date:  2008-07-18       Impact factor: 4.200

3.  Absorption rate vs. exposure: which is more useful for bioequivalence testing?

Authors:  T N Tozer; F Y Bois; W W Hauck; M L Chen; R L Williams
Journal:  Pharm Res       Date:  1996-03       Impact factor: 4.200

4.  Prediction of pharmacokinetic parameters and the assessment of their variability in bioequivalence studies by artificial neural networks.

Authors:  J Opara; S Primozic; P Cvelbar
Journal:  Pharm Res       Date:  1999-06       Impact factor: 4.200

5.  No Dose Adjustment is Recommended for Digoxin, Warfarin, Atorvastatin or a Combination Oral Contraceptive When Coadministered with Dulaglutide.

Authors:  Amparo de la Peña; Xuewei Cui; Jeanne Geiser; Corina Loghin
Journal:  Clin Pharmacokinet       Date:  2017-11       Impact factor: 6.447

6.  Two-Stage Adaptive Designs for Three-Treatment Bioequivalence Studies.

Authors:  Michael J Grayling; Adrian P Mander; James M S Wason
Journal:  Stat Biopharm Res       Date:  2019-09-06       Impact factor: 1.452

7.  Effect of nebicapone on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.

Authors:  Luis Almeida; Amílcar Falcão; Manuel Vaz-da-Silva; Teresa Nunes; Ana-Teresa Santos; José-Francisco Rocha; Carla Neta; Tice Macedo; C Fontes-Ribeiro; P Soares-da-Silva
Journal:  Eur J Clin Pharmacol       Date:  2008-08-06       Impact factor: 2.953

8.  Bioavailability and bioequivalence of two enteric-coated formulations of omeprazole in fasting and fed conditions.

Authors:  Manuel Vaz-da-Silva; Ana I Loureiro; Teresa Nunes; Joana Maia; Susana Tavares; Amilcar Falcão; Pedro Silveira; Luis Almeida; Patricio Soares-da-Silva
Journal:  Clin Drug Investig       Date:  2005       Impact factor: 2.859

9.  Pharmacokinetics and comparative bioavailability of two metformin formulations after single-dose administration in healthy subjects.

Authors:  Ivanka Atanasova; Kristina Bozhinova; Denitza Todorova; Dimiter Terziivanov
Journal:  Clin Drug Investig       Date:  2003       Impact factor: 2.859

10.  Relative Bioavailability of Two Enteric-Coated Formulations of Omeprazole following Repeated Doses in Healthy Volunteers.

Authors:  M Vaz-da-Silva; D Hainzl; L Almeida; A Dolgner; P Silveira; J Maia; P Soares-da-Silva
Journal:  Clin Drug Investig       Date:  2001-03       Impact factor: 2.859

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.